HighVista Strategies LLC Takes Position in Catalent, Inc. (NYSE:CTLT)

HighVista Strategies LLC acquired a new position in Catalent, Inc. (NYSE:CTLT) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 75,600 shares of the company’s stock, valued at approximately $4,251,000. Catalent accounts for 1.6% of HighVista Strategies LLC’s holdings, making the stock its 8th largest position.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Lindbrook Capital LLC grew its holdings in Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalent in the second quarter worth about $42,000. Mather Group LLC. purchased a new position in Catalent during the 1st quarter valued at about $52,000. Longfellow Investment Management Co. LLC raised its position in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the period.

Insiders Place Their Bets

In other news, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the transaction, the insider now directly owns 29,974 shares in the company, valued at $1,785,251.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Scott Gunther sold 666 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the sale, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ricky Hopson sold 662 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the sale, the insider now owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,409 shares of company stock worth $782,923. 0.31% of the stock is currently owned by company insiders.

Catalent Stock Down 0.2 %

NYSE:CTLT opened at $60.00 on Monday. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The company has a market capitalization of $10.86 billion, a PE ratio of -9.84, a P/E/G ratio of 1.88 and a beta of 1.15. The firm’s 50-day moving average price is $59.48 and its 200-day moving average price is $57.22. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.77.

Analyst Upgrades and Downgrades

A number of analysts recently commented on CTLT shares. Barclays raised their price target on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. StockNews.com began coverage on shares of Catalent in a research report on Wednesday, September 18th. They issued a “sell” rating for the company. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $58.08.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.